Veru Inc. (NASDAQ: VERU) will release earnings results for its fourth quarter before the opening bell on Wednesday, Dec. 17.

Additional information on the meeting can be found on the following website: https://obesityweek.org/. About Veru Inc. Veru is a late clinical stage biopharmaceutical ...

MIAMI - Veru Inc. (NASDAQ:VERU), a $52.3 million market cap biopharmaceutical company that has seen remarkable revenue growth of 337% over the last twelve months, announced Tuesday that the FDA has ...

Veru Inc. VERU recently announced the selection of a novel modified-release oral formulation for enobosarm for chronic weight loss management. Enobosarm is a selective androgen receptor modulator ...

Veru Inc. (VERU) reported its third-quarter financial results for fiscal year 2025, revealing a substantial earnings per share (EPS) miss. The company posted an EPS of -$0.50, falling short of the ...

Veru Inc (NASDAQ:VERU) is set to release its Q3 2025 earnings on Aug 12, 2025. The consensus estimate for Q3 2025 revenue is $0.65 million, and the earnings are expected to come in at -$0.05 per share ...

Jan 27 (Reuters) - Veru (VERU.O), opens new tab said on Monday its experimental drug in combination with Novo Nordisk's (NOVOb.CO), opens new tab weight-loss treatment Wegovy, helped preserve muscle ...

Veru Inc. (NASDAQ:VERU) shares jumped on Tuesday after the company disclosed the sale of its FC2 Female Condom (Internal Condom) business to clients managed by Riva Ridge Capital Management LP and ...

Veru knows the route that its once-dismissed respiratory distress drug has to take to pacify regulators, but the biotech needs some more cash to hit the road. That’s according to the company’s latest ...